Key facts
| Company | JJLBRO |
|---|---|
| FDA office | Center for Drug Evaluation and Research (CDER) |
| Letter date | June 17, 2026 |
| Subject / product | Unapproved New Drugs/Misbranded |
| CFR citations | FDA Warning Letter |
| Response due | 15 working days from receipt (standard FDA warning-letter requirement) |
| Reference / source ID | jjlbro-729873-06172026 |
Violations explained
FDA Warning Letter — Violations FDA cited at JJLBRO
WARNING LETTER JJLBRO MARCS-CMS 729873 — June 17, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: JJLBRO Romvy E-Ticaret Limited Sirketi Oba Başaranlar Sk. No: 16 07400 / Antalya Turkey eroxoninmed@gmail.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 17, 2026 WARNING LETTER Reference Number: 729873 To JJLBRO and Romvy E-Ticaret Limited Sirketi: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA Review Violations were identified and documented during a review of your website https://jjlbro.com/ in May 2026. We also reviewed your Amazon storefront in May 2026. 1 Based on our review, “Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of your website, “Men’s Foreskin Repair Gel,” “Size’Up Chrono Erect,” “Penile Health Cream,” “Men’s External Delayed Spray,” and “Men’s Penis XXL Care Cream” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following: Men’s Foreskin Repair Gel On the webpage https://jjlbro.com/products/mens-extra-power-foreskin-repair-enhancement-gel?variant=41998671478878: “DOUBLE LINE CARE, DIRECT HIT PHIMOSIS” “ABSORPTION OF INTERNAL ADHESIONS” “TO PROMOTE THE VITALITY OF PRIVATE CELLS FROM THE CONGENITAL PHIMOSIS” Size’Up Chrono Erect On the webpage https://jjlbro.com/products/mens-size-up-chrono-erect-enlargement-cream-extra-power-massage-gel-oil-for-huge-thickness-strength-and-prolonged-performance?variant=41998765916254: “Proven Size Enhancement: Clinically . . . shown to help promote blood flow and stimulate cell growth, leading to visible results in size enhancement with consistent use.” “Prolonged Performance: Men’s Size Up Chrono Erect Enlargement Cream supports prolonged performance by stimulating circulation and energy flow, improving stamina and endurance.” Penile Health Cream On the webpage https://jjlbro.com/products/male-performance-med3000-enhancement-gel?variant=41998765850718: “BOOST MUSCLE STRENGTH” “ENHANCES LIBIDO AND PLEASURE” “INCREASE ENERGY AND STAMINA” “IMPROVE MALE REPRODUCTIVE HEALTH” “Naturally Boosts Energy, Libido, Fertility, Mood, and Hormonal Balance.” “Enhances intim
What happens next
JJLBRO is expected to respond to FDA in writing, typically within 15 working days of the letter date, describing the specific corrective and preventive actions taken or planned for each violation cited. FDA reviews that response and any follow-up evidence, and can conduct a re-inspection to confirm the corrections were actually made. If FDA judges the response inadequate, or the underlying conditions serious enough, further action can follow, including product seizure, injunction, import alert, or civil penalties; many Warning Letters are resolved through corrective action alone. This page reflects the Warning Letter as issued and will not reflect any subsequent correction unless FDA publishes a follow-up record. FDA issues Warning Letters after an inspection or other review when it believes a firm has significantly violated FDA regulations; the letter itself is a notice, not a final adjudication.
JJLBRO’s FDA history
Argus HQ has recorded 1 total FDA action tied to JJLBRO: 1 warning letter, 0 recalls, 0 approval records, and 0 Form 483 inspection citations.
Full letter text
Read the rest of the full text
Frequently asked questions
- What is an FDA Warning Letter?
- An FDA Warning Letter notifies a company that FDA believes it has significantly violated FDA regulations and that prompt corrective action is required. It is issued after an inspection, sample analysis, or other FDA review, and is a notice -- not a final legal determination and not itself a penalty.
- Does this Warning Letter mean JJLBRO violated the law?
- FDA's letter documents violations it believes it found at JJLBRO. A Warning Letter is not a final adjudication of guilt; the company has an opportunity to respond and correct the cited issues, and many Warning Letters are resolved without further enforcement once FDA confirms adequate correction.
- What happens after a Warning Letter is issued?
- The firm generally must respond in writing within 15 working days; FDA reviews the response and can escalate to seizure, injunction, or import alert if it judges the response inadequate. Many Warning Letters are resolved through corrective action alone.
- Has JJLBRO had other FDA enforcement actions?
- This is the only FDA action Argus HQ has on file for JJLBRO so far. Argus ingests new FDA enforcement records daily.
Get the next warning letter in this therapeutic area before your team hears about it secondhand.
Weekly briefing, free. Upgrade any time for daily or real-time delivery.
Related enforcement actions
Full FDA history for JJLBRO- Warning letter (recent): Med Shop Inc / www.medshopinc.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): ketaminetroches.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketdaxandrugs / www.ketdaxandrugs.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Legit Ketamine Suppliers / www.legitketaminesuppliers.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Store / www.ketaminestore.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Buy Keta Online / www.buyketaonline.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Troche Store / www.ketaminetrochestore.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): All Ketamine HCL / www.allketaminehcl.com — Unapproved New Drugs/Misbranded (2026-06-23) →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites JJLBRO in June 17, 2026 Warning Letter — Unapproved New Drugs/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/warning-letter/jjlbro-729873-2026-06-17
"FDA Cites JJLBRO in June 17, 2026 Warning Letter — Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/warning-letter/jjlbro-729873-2026-06-17.
Argus HQ Research. "FDA Cites JJLBRO in June 17, 2026 Warning Letter — Unapproved New Drugs/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/warning-letter/jjlbro-729873-2026-06-17.
@misc{argushq_argushq_ai_warning_letter_jjlbro_729873_2026_06_17_2026,
title = {FDA Cites JJLBRO in June 17, 2026 Warning Letter — Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/warning-letter/jjlbro-729873-2026-06-17},
note = {Accessed: July 13, 2026}
}Source: FDA.gov — Warning Letters ↗

